Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 58

1.

Overuse of Cystoscopic Surveillance among Patients with Low-Risk Non-Muscle-Invasive Bladder Cancer - A National Study of Patient, Provider, and Facility Factors.

Han DS, Lynch KE, Chang JW, Sirovich B, Robertson DJ, Swanton AR, Seigne JD, Goodney PP, Schroeck FR.

Urology. 2019 May 27. pii: S0090-4295(19)30448-0. doi: 10.1016/j.urology.2019.04.036. [Epub ahead of print]

PMID:
31145947
2.

The impact of frequent cystoscopy on surgical care and cancer outcomes among patients with low-risk, non-muscle-invasive bladder cancer.

Schroeck FR, Lynch KE, Li Z, MacKenzie TA, Han DS, Seigne JD, Robertson DJ, Sirovich B, Goodney PP.

Cancer. 2019 May 23. doi: 10.1002/cncr.32185. [Epub ahead of print]

PMID:
31120559
3.

Urologist Practice Structure and Spending for Prostate Cancer Care.

Modi PK, Herrel LA, Kaufman SR, Yan P, Borza T, Skolarus TA, Schroeck FR, Hollenbeck BK, Shahinian VB.

Urology. 2019 Apr 25. pii: S0090-4295(19)30372-3. doi: 10.1016/j.urology.2019.03.029. [Epub ahead of print]

PMID:
31029672
4.

MicroRNA Dysregulation and Non-Muscle-Invasive Bladder Cancer Prognosis.

Andrew AS, Karagas MR, Schroeck FR, Marsit CJ, Schned AR, Pettus JR, Armstrong DA, Seigne JD.

Cancer Epidemiol Biomarkers Prev. 2019 Apr;28(4):782-788. doi: 10.1158/1055-9965.EPI-18-0884. Epub 2019 Jan 30.

PMID:
30700445
5.

Extent of Risk-Aligned Surveillance for Cancer Recurrence Among Patients With Early-Stage Bladder Cancer.

Schroeck FR, Lynch KE, Chang JW, MacKenzie TA, Seigne JD, Robertson DJ, Goodney PP, Sirovich B.

JAMA Netw Open. 2018 Sep;1(5). pii: e183442. doi: 10.1001/jamanetworkopen.2018.3442. Epub 2018 Sep 28.

6.

Anesthetic challenges and outcomes for procedures in the intraoperative magnetic resonance imaging suite: A systematic review.

Schroeck H, Welch TL, Rovner MS, Johnson HA, Schroeck FR.

J Clin Anesth. 2019 May;54:89-101. doi: 10.1016/j.jclinane.2018.10.022. Epub 2018 Nov 8. Review.

PMID:
30415150
7.

Geographic Variation in Cystoscopy Rates for Suspected Bladder Cancer between Female and Male Medicare Beneficiaries.

Han DS, Zhou W, Seigne JD, Lynch KE, Schroeck FR.

Urology. 2018 Dec;122:83-88. doi: 10.1016/j.urology.2018.08.011. Epub 2018 Aug 20.

PMID:
30138684
8.

Uncoupling Diagnosis and Treatment of Incidentally Imaged Renal Masses-Reply.

Welch HG, Schroeck FR.

JAMA Intern Med. 2018 May 1;178(5):729. doi: 10.1001/jamainternmed.2018.1183. No abstract available.

PMID:
29801139
9.

Harnessing the Synergy Between Improvement Science and Implementation Science in Cancer: A Call to Action.

Koczwara B, Stover AM, Davies L, Davis MM, Fleisher L, Ramanadhan S, Schroeck FR, Zullig LL, Chambers DA, Proctor E.

J Oncol Pract. 2018 Jun;14(6):335-340. doi: 10.1200/JOP.17.00083. Epub 2018 May 14. No abstract available.

10.

Impact of Accountable Care Organizations on Diagnostic Testing for Prostate Cancer.

Luckenbaugh AN, Hollenbeck BK, Kaufman SR, Yan P, Herrel LA, Skolarus TA, Norton EC, Schroeck FR, Jacobs BL, Miller DC, Hollingsworth JM, Shahinian VB, Borza T.

Urology. 2018 Jun;116:68-75. doi: 10.1016/j.urology.2018.01.056. Epub 2018 Apr 6.

11.

Implementing risk-aligned bladder cancer surveillance care.

Schroeck FR, Smith N, Shelton JB.

Urol Oncol. 2018 May;36(5):257-264. doi: 10.1016/j.urolonc.2017.12.016. Epub 2018 Feb 13. Review.

12.

Regional Variation of Computed Tomographic Imaging in the United States and the Risk of Nephrectomy.

Welch HG, Skinner JS, Schroeck FR, Zhou W, Black WC.

JAMA Intern Med. 2018 Feb 1;178(2):221-227. doi: 10.1001/jamainternmed.2017.7508.

13.

Development of a Natural Language Processing Engine to Generate Bladder Cancer Pathology Data for Health Services Research.

Schroeck FR, Patterson OV, Alba PR, Pattison EA, Seigne JD, DuVall SL, Robertson DJ, Sirovich B, Goodney PP.

Urology. 2017 Dec;110:84-91. doi: 10.1016/j.urology.2017.07.056. Epub 2017 Sep 12.

14.

Assembling and validating data from multiple sources to study care for Veterans with bladder cancer.

Schroeck FR, Sirovich B, Seigne JD, Robertson DJ, Goodney PP.

BMC Urol. 2017 Sep 6;17(1):78. doi: 10.1186/s12894-017-0271-x.

15.

Urologist Practice Affiliation and Intensity-modulated Radiation Therapy for Prostate Cancer in the Elderly.

Hollenbeck BK, Kaufman SR, Yan P, Herrel LA, Borza T, Schroeck FR, Jacobs BL, Skolarus TA, Shahinian VB.

Eur Urol. 2018 Apr;73(4):491-498. doi: 10.1016/j.eururo.2017.08.001. Epub 2017 Aug 18.

16.

The Burden of Cystoscopic Bladder Cancer Surveillance: Anxiety, Discomfort, and Patient Preferences for Decision Making.

Koo K, Zubkoff L, Sirovich BE, Goodney PP, Robertson DJ, Seigne JD, Schroeck FR.

Urology. 2017 Oct;108:122-128. doi: 10.1016/j.urology.2017.07.016. Epub 2017 Jul 21.

17.

Cost of New Technologies in Prostate Cancer Treatment: Systematic Review of Costs and Cost Effectiveness of Robotic-assisted Laparoscopic Prostatectomy, Intensity-modulated Radiotherapy, and Proton Beam Therapy.

Schroeck FR, Jacobs BL, Bhayani SB, Nguyen PL, Penson D, Hu J.

Eur Urol. 2017 Nov;72(5):712-735. doi: 10.1016/j.eururo.2017.03.028. Epub 2017 Mar 31. Review.

18.

The early adoption of intensity-modulated radiotherapy and stereotactic body radiation treatment among older Medicare beneficiaries with prostate cancer.

Jacobs BL, Yabes JG, Lopa SH, Heron DE, Chang CH, Schroeck FR, Bekelman JE, Kahn JM, Nelson JB, Barnato AE.

Cancer. 2017 Aug 1;123(15):2945-2954. doi: 10.1002/cncr.30574. Epub 2017 Mar 16.

19.

Health Care Integration and Quality among Men with Prostate Cancer.

Herrel LA, Kaufman SR, Yan P, Miller DC, Schroeck FR, Skolarus TA, Shahinian VB, Hollenbeck BK.

J Urol. 2017 Jan;197(1):55-60. doi: 10.1016/j.juro.2016.07.040. Epub 2016 Jul 15.

20.

Early Stage Bladder Cancer: Do Pathology Reports Tell Us What We Need to Know?

Schroeck FR, Pattison EA, Denhalter DW, Patterson OV, DuVall SL, Seigne JD, Robertson DJ, Sirovich B, Goodney PP.

Urology. 2016 Dec;98:58-63. doi: 10.1016/j.urology.2016.07.040. Epub 2016 Aug 30.

21.

Editorial Comment.

Schroeck FR, Sirovich BE.

Urology. 2015 Dec;86(6):1198-9. doi: 10.1016/j.urology.2015.07.041. No abstract available.

PMID:
26719119
22.

Understanding hospital readmission intensity after radical cystectomy.

Skolarus TA, Jacobs BL, Schroeck FR, He C, Helfand AM, Helm J, Hu M, Lavieri M, Hollenbeck BK.

J Urol. 2015 May;193(5):1500-6. doi: 10.1016/j.juro.2014.10.107. Epub 2014 Nov 4.

PMID:
25451833
23.

Technology diffusion and prostate cancer quality of care.

Schroeck FR, Kaufman SR, Jacobs BL, Skolarus TA, Zhang Y, Hollenbeck BK.

Urology. 2014 Nov;84(5):1066-72. doi: 10.1016/j.urology.2014.06.067. Epub 2014 Oct 24.

24.

Receipt of best care according to current quality of care measures and outcomes in men with prostate cancer.

Schroeck FR, Kaufman SR, Jacobs BL, Hollenbeck BK.

J Urol. 2015 Feb;193(2):500-4. doi: 10.1016/j.juro.2014.08.001. Epub 2014 Aug 7.

25.

Managed care and the dissemination of robotic prostatectomy.

Zhang Y, Hollenbeck BK, Schroeck FR, Jacobs BL.

Surg Innov. 2014 Dec;21(6):566-71. doi: 10.1177/1553350614524841. Epub 2014 Jul 21.

26.

Adherence to performance measures and outcomes among men treated for prostate cancer.

Schroeck FR, Kaufman SR, Jacobs BL, Skolarus TA, Miller DC, Montgomery JS, Weizer AZ, Hollenbeck BK.

J Urol. 2014 Sep;192(3):743-8. doi: 10.1016/j.juro.2014.03.091. Epub 2014 Mar 25.

27.

Intensity-modulated radiation therapy for prostate cancer.

Jacobs BL, Schroeck FR, Hollenbeck BK.

N Engl J Med. 2014 Feb 13;370(7):679. doi: 10.1056/NEJMc1314524. No abstract available.

PMID:
24521127
28.

Variation in use of active surveillance among men undergoing expectant treatment for early stage prostate cancer.

Filson CP, Schroeck FR, Ye Z, Wei JT, Hollenbeck BK, Miller DC.

J Urol. 2014 Jul;192(1):75-80. doi: 10.1016/j.juro.2014.01.105. Epub 2014 Feb 8.

PMID:
24518783
29.

The impact of technology diffusion on treatment for prostate cancer.

Schroeck FR, Kaufman SR, Jacobs BL, Zhang Y, Weizer AZ, Montgomery JS, Gilbert SM, Strope SA, Hollenbeck BK.

Med Care. 2013 Dec;51(12):1076-84. doi: 10.1097/MLR.0000000000000019.

30.

Regional variation in quality of prostate cancer care.

Schroeck FR, Kaufman SR, Jacobs BL, Skolarus TA, Hollingsworth JM, Shahinian VB, Hollenbeck BK.

J Urol. 2014 Apr;191(4):957-62. doi: 10.1016/j.juro.2013.10.066. Epub 2013 Oct 19.

31.

Reply by the authors.

Schroeck FR, Wei JT.

Urology. 2013 Oct;82(4):981. doi: 10.1016/j.urology.2013.06.001. No abstract available.

PMID:
24075001
32.

Use of advanced treatment technologies among men at low risk of dying from prostate cancer.

Jacobs BL, Zhang Y, Schroeck FR, Skolarus TA, Wei JT, Montie JE, Gilbert SM, Strope SA, Dunn RL, Miller DC, Hollenbeck BK.

JAMA. 2013 Jun 26;309(24):2587-95. doi: 10.1001/jama.2013.6882.

33.

Understanding variation in the quality of the surgical treatment of prostate cancer.

Schroeck FR, Jacobs BL, Hollenbeck BK.

Am Soc Clin Oncol Educ Book. 2013:278-83. doi: 10.1200/EdBook_AM.2013.33.278. Review.

34.

Technology diffusion and diagnostic testing for prostate cancer.

Schroeck FR, Kaufman SR, Jacobs BL, Skolarus TA, Miller DC, Weizer AZ, Montgomery JS, Wei JT, Shahinian VB, Hollenbeck BK.

J Urol. 2013 Nov;190(5):1715-20. doi: 10.1016/j.juro.2013.05.007. Epub 2013 May 10.

35.

Differential adoption of laser prostatectomy for treatment of benign prostatic hyperplasia.

Schroeck FR, Hollingsworth JM, Hollenbeck BK, Jacobs BL, Suskind AM, Sarma AV, Wei JT.

Urology. 2013 Jun;81(6):1177-82. doi: 10.1016/j.urology.2013.01.051. Epub 2013 Mar 19.

36.

Editorial comment.

Schroeck FR, Skolarus TA.

Urology. 2013 Apr;81(4):751. doi: 10.1016/j.urology.2012.12.045. No abstract available.

PMID:
23465169
37.

Managed care and the diffusion of intensity-modulated radiotherapy for prostate cancer.

Jacobs BL, Zhang Y, Skolarus TA, Wei JT, Montie JE, Schroeck FR, Hollenbeck BK.

Urology. 2012 Dec;80(6):1236-42. doi: 10.1016/j.urology.2012.09.006.

38.

Certificate of need legislation and the dissemination of robotic surgery for prostate cancer.

Jacobs BL, Zhang Y, Skolarus TA, Wei JT, Montie JE, Schroeck FR, Hollenbeck BK.

J Urol. 2013 Jan;189(1):80-5. doi: 10.1016/j.juro.2012.08.185. Epub 2012 Nov 16.

PMID:
23164388
39.

Editorial comment.

Schroeck FR.

J Urol. 2012 Dec;188(6):2218. doi: 10.1016/j.juro.2012.08.204. Epub 2012 Oct 22. No abstract available.

PMID:
23083658
40.

Testing for the recurrent HOXB13 G84E germline mutation in men with clinical indications for prostate biopsy.

Schroeck FR, Zuhlke KA, Siddiqui J, Siddiqui R, Cooney KA, Wei JT.

J Urol. 2013 Mar;189(3):849-53. doi: 10.1016/j.juro.2012.09.117. Epub 2012 Oct 2.

41.

Population based trends in the surgical treatment of benign prostatic hyperplasia.

Schroeck FR, Hollingsworth JM, Kaufman SR, Hollenbeck BK, Wei JT.

J Urol. 2012 Nov;188(5):1837-41. doi: 10.1016/j.juro.2012.07.049. Epub 2012 Sep 19.

42.

Certificate of need regulations and the diffusion of intensity-modulated radiotherapy.

Jacobs BL, Zhang Y, Skolarus TA, Wei JT, Montie JE, Schroeck FR, Hollenbeck BK.

Urology. 2012 Nov;80(5):1015-20. doi: 10.1016/j.urology.2012.07.042. Epub 2012 Sep 19.

43.

Introduction of laser technology and procedure use for benign prostatic hyperplasia: data from Florida.

Schroeck FR, Hollingsworth JM, Kaufman SR, Hollenbeck BK, Wei JT.

Urology. 2012 Sep;80(3):678-83. doi: 10.1016/j.urology.2012.05.025. Epub 2012 Jul 27.

44.

Are repeat prostate biopsies safe? A cohort analysis from the SEARCH database.

Kopp RP, Stroup SP, Schroeck FR, Freedland SJ, Millard F, Terris MK, Aronson WJ, Presti JC Jr, Amling CL, Kane CJ.

J Urol. 2012 Jun;187(6):2056-60. doi: 10.1016/j.juro.2012.01.083. Epub 2012 Apr 11.

45.

Pretreatment expectations of patients undergoing robotic assisted laparoscopic or open retropubic radical prostatectomy.

Schroeck FR, Krupski TL, Stewart SB, Bañez LL, Gerber L, Albala DM, Moul JW.

J Urol. 2012 Mar;187(3):894-8. doi: 10.1016/j.juro.2011.10.135. Epub 2012 Jan 15.

PMID:
22245326
46.

Factors predicting early and late phase decline of sexual health-related quality of life following radical prostatectomy.

Kimura M, Bañez LL, Schroeck FR, Gerber L, Qi J, Satoh T, Baba S, Robertson CN, Walther PJ, Donatucci CF, Moul JW, Polascik TJ.

J Sex Med. 2011 Oct;8(10):2935-43. doi: 10.1111/j.1743-6109.2011.02387.x. Epub 2011 Jul 19.

PMID:
21771284
47.

Simultaneously detected bilateral testicular cancer of different histopathological origin--a challenging situation for the urologist.

Hammerich KH, Schroeck FR, West D, Moul JW.

Oncology (Williston Park). 2010 Jul;24(8):757-60. Review.

48.

Re-calibration and external validation of an existing nomogram to predict aggressive recurrences after radical prostatectomy.

Schroeck FR, Kattan MW, Moul JW, Aronson WJ, Presti JC Jr, Terris MK, Kane CJ, Amling CL, Sun L, Freedland SJ.

BJU Int. 2010 Jun;105(12):1654-9. doi: 10.1111/j.1464-410X.2009.09060.x. Epub 2009 Nov 13.

49.

Factors predicting prostatic biopsy Gleason sum under grading.

Stackhouse DA, Sun L, Schroeck FR, Jayachandran J, Caire AA, Acholo CO, Robertson CN, Albala DM, Polascik TJ, Donatucci CF, Maloney KE, Moul JW.

J Urol. 2009 Jul;182(1):118-22; discussion 123-4. doi: 10.1016/j.juro.2009.02.127. Epub 2009 May 17.

PMID:
19447436
50.

Robot-assisted laparoscopic prostatectomy is not associated with early postoperative radiation therapy.

Chino J, Schroeck FR, Sun L, Lee WR, Albala DM, Moul JW, Koontz BF.

BJU Int. 2009 Nov;104(10):1496-500. doi: 10.1111/j.1464-410X.2009.08588.x. Epub 2009 Apr 17.

Supplemental Content

Loading ...
Support Center